Delta-opioid agonist SNC-121 protects retinal ganglion cell function in a chronic ocular hypertensive rat model

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 3, 2013, Pages 1816-1828

  Abdul, Yasir ^a   Akhter, Naseem ^a   Husain, Shahid ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELTA OPIATE RECEPTOR AGONIST; MITOGEN ACTIVATED PROTEIN KINASE; SNC 121; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL FUNCTION; CONTROLLED STUDY; ELECTRORETINOGRAPHY; FEMALE; FLUORESCENCE MICROSCOPY; GLAUCOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL; VISUAL STIMULATION; WESTERN BLOTTING;

ANIMALS; ASTROCYTES; BENZAMIDES; BLOTTING, WESTERN; CELL SURVIVAL; CHRONIC DISEASE; CYTOPROTECTION; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; FEMALE; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; INTRAOCULAR PRESSURE; MALE; NEUROPROTECTIVE AGENTS; OCULAR HYPERTENSION; OPTIC DISK; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PIPERAZINES; RATS; RATS, INBRED BN; RECEPTORS, OPIOID, DELTA; RETINA; RETINAL GANGLION CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875445970     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10741     Document Type: Article

References (45)

1. Quigley HA, Green WR. The histology of human glaucoma cupping and optic nerve damage: clinicopathologic correlation in 21 eyes. Ophthalmology. 1979;86:1803-1830.
2. Boland MV, Quigley HA. Risk factors and open-angle glaucoma: classification and application. J Glaucoma. 2007;16:406-418.
3. Liu Q, Ju WK, Crowston JG, et al. Oxidative stress is an early event in hydrostatic pressure induced retinal ganglion cell damage. Invest Ophthalmol Vis Sci. 2007;48:4580-4589.
4. Ju WK, Kim KY, Angert M, et al. Memantine blocks mitochondrial OPA1 and cytochrome c release and subsequent apoptotic cell death in glaucomatous retina. Invest Ophthalmol Vis Sci. 2009;50:707-716.
5. Nucci C, Tartaglione R, Rombola L, Morrone LA, Fazzi E, Bagetta G. Neurochemical evidence to implicate elevated glutamate in the mechanisms of high intraocular pressure (IOP)-induced retinal ganglion cell death in rat. Neurotoxicology. 2005;26:935-941.
6. Yang X, Luo C, Cai J, et al. Neurodegenerative and inflammatory pathway components linked to TNF-alpha/TNFR1 signaling in the glaucomatous human retina. Invest Ophthalmol Vis Sci. 2011;52:8442-8454.
7. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retinal Eye Res. 2006; 25:490-513.
8. Shohami E, Ginis I, Hallenbeck JM. Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev. 1999;10:119-130.
9. Tezel G, Li LY, Patil RV, Wax MB. TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci. 2001;42:1787-1794.
10. Yuan L, Neufeld AH. Tumor necrosis factor-alpha: a potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head. Glia. 2000;32:42-50.
11. Husain S, Potter DE. The opioidergic system: potential roles and therapeutic indications in the eye. J Ocul Pharmacol Ther. 2008;24:117-140.
12. Schultz JE, Gross GJ. Opioids and cardioprotection. Pharmacol Ther. 2001;89:123-137.
13. Ferri S, Speroni E, Candeletti S, et al. Protection by opioids against gastric lesions caused by necrotizing agents. Pharmacology. 1988;36:140-144.
14. Mayfield KP, D'Alecy LG. Delta-1 opioid agonist acutely increases hypoxic tolerance. J Pharmacol Exp Ther. 1994; 268:683-688.
15. Husain S, Potter DE, Crosson CE. Opioid receptor-activation: retina protected from ischemic injury. Invest Ophthalmol Vis Sci. 2009;50:3853-3859.
16. Husain S, Abdul Y, Crosson CE. Preservation of retina ganglion cell function by morphine in a chronic ocular-hypertensive rat model. Invest Ophthalmol Vis Sci. 2012;53:4289-4298.
17. Husain S, Liou GI, Crosson CE. Opioid-receptor-activation: suppression of ischemia/reperfusion-induced production of TNF-{alpha} in the retina. Invest Ophthalmol Vis Sci. 2011;52: 2577-2583.
18. Morrison JC, Moore CG, Deppmeier LM, Gold BG, Meshul CK, Johnson EC. A rat model of chronic pressure-induced optic nerve damage. Exp Eye Res. 1997;64:85-96.
19. Husain S, Whitlock NA, Rice DS, Crosson CE. Effects of latanoprost on rodent intraocular pressure. Exp Eye Res. 2006; 83:1453-1458.
20. McKinnon SJ, Lehman DM, Tahzib NG, et al. Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol Ther. 2002;5:780-787.
21. Isayama T, McLaughlin PJ, Zagon IS. Endogenous opioids regulate cell proliferation in the retina of developing rat. Brain Res. 1991;544:79-85.
22. Husain S, Abdul Y, Potter DE. Non-analgesic effects of opioids: neuroprotection in the retina. Curr Pharm Des. 2012;18: 5919-5926.
23. Husain S, Potter DE. The opioidergic system: potential roles and therapeutic indications in the eye. J Ocul Pharmacol Ther. 2008;24:117-140.
24. Chen TY, Goyagi T, Toung TJ, et al. Prolonged opportunity for ischemic neuroprotection with selective kappa-opioid receptor agonist in rats. Stroke. 2004;35:1180-1185.
25. Gross ER, Hsu AK, Gross GJ. Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ Res. 2004;94:960-966.
26. Zhang J, Haddad GG, Xia Y. Delta-, but not mu-and kappa-, opioid receptor activation protects neocortical neurons from glutamate-induced excitotoxic injury. Brain Res. 2000;885: 143-153.
27. Iwata M, Inoue S, Kawaguchi M, Nakamura M, Konishi N, Furuya H. Effects of delta-opioid receptor stimulation and inhibition on hippocampal survival in a rat model of forebrain ischaemia. British J Anaesth. 2007;99:538-546.
28. Yang Y, Xia X, Zhang Y, et al. delta-Opioid receptor activation attenuates oxidative injury in the ischemic rat brain. BMC Biol. 2009;7:1-9.
29. Thathiah A, De Strooper B. The role of G protein-coupled receptors in the pathology of Alzheimer's disease. Nat Rev Neurosci. 2011;12:73-87.
30. Mabrouk OS, Marti M, Salvadori S, Morari M. The novel delta opioid receptor agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigrothalamic pathway. Neuroscience. 2009;164:360-369.
31. Holder GE. Pattern electroretinography (PERG) and an integrated approach to visual pathway diagnosis. Prog Retinal Eye Res. 2001;20:531-561.
32. Porciatti V. The mouse pattern electroretinogram. Doc Ophthalmol. 2007;115:145-153.
33. Wanger P, Persson HE. Pattern-reversal electroretinograms in unilateral glaucoma. Invest Ophthalmol Vis Sci. 1983;24:749-753.
34. Dortch-Carnes J, Potter DE. Effect of bremazocine, a kappaopioid receptor agonist, on inositol phosphate formation in isolated iris-ciliary bodies. Pharmacology. 2002;66:100-106.
35. Dortch-Carnes J, Potter DE. Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties. CNS Drug Rev. 2005;11:195-212.
36. Stagni E, Bucolo C, Motterlini R, Drago F. Morphine-induced ocular hypotension is modulated by nitric oxide and carbon monoxide: role of mu3 receptors. J Ocul Pharmacol Ther. 2010;26:31-35.
37. Burt AR, Carr IC, Mullaney I, Anderson NG, Milligan G. Agonist activation of p42 and p44 mitogen-activated protein kinases following expression of the mouse delta opioid receptor in Rat-1 fibroblasts: effects of receptor expression levels and comparisons with G-protein activation. Biochem J. 1996;320: 227-235.
38. Park EM, Joh TH, Volpe BT, Chu CK, Song G, Cho S. A neuroprotective role of extracellular signal-regulated kinase in N-acetyl-O-methyldopamine-treated hippocampal neurons after exposure to in vitro and in vivo ischemia. Neuroscience. 2004;123:147-154.
39. Hetman M, Kanning K, Cavanaugh JE, Xia Z. Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. J Biol Chem. 1999;274:22569-22580.
40. Ke S, Dian-san S, Xiang-rui W. Delta opioid agonist [D-Ala2, DLeu5] enkephalin (DADLE) reduced oxygen-glucose deprivation caused neuronal injury through the MAPK pathway. Brain Res. 2009;1292:100-106.
41. Takeda K, Ichijo H. Neuronal p38 MAPK signalling: an emerging regulator of cell fate and function in the nervous system. Genes Cells. 2002;7:1099-1111.
42. Legos JJ, McLaughlin B, Skaper SD, et al. The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury. Eur J Pharmacol. 2002;447:37-42.
43. Legos JJ, Erhardt JA, White RF, et al. SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia. Brain Res. 2001;892:70-77.
44. Kikuchi M, Tenneti L, Lipton SA. Role of p38 mitogen-activated protein kinase in axotomy-induced apoptosis of rat retinal ganglion cells. J Neurosci. 2000;20:5037-5044.
45. Levkovitch-Verbin H, Harizman N, Dardik R, Nisgav Y, Vander S, Melamed S. Regulation of cell death and survival pathways in experimental glaucoma. Exp Eye Res. 2007;85:250-258.